000963 华东医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.40614.26515.92514.32814.217
总资产报酬率 ROA (%)4.7108.8789.8398.7758.590
投入资产回报率 ROIC (%)6.07611.57113.04711.91611.856

边际利润分析
销售毛利率 (%)32.79932.35933.21132.40031.903
营业利润率 (%)10.2339.41910.3208.5008.117
息税前利润/营业总收入 (%)10.0919.25310.3188.6588.245
净利润/营业总收入 (%)8.3387.8218.3387.0076.715

收益指标分析
经营活动净收益/利润总额(%)100.894105.145102.585102.189103.790
价值变动净收益/利润总额(%)0.027-3.432-3.003-6.736-3.731
营业外收支净额/利润总额(%)-2.125-2.276-0.5400.377-1.001

偿债能力分析
流动比率 (X)1.6091.6221.5261.7121.730
速动比率 (X)1.2351.1991.1801.3151.288
资产负债率 (%)35.51035.52237.79235.59338.522
带息债务/全部投入资本 (%)16.33916.18018.14313.55214.209
股东权益/带息债务 (%)501.865507.340441.461620.086578.494
股东权益/负债合计 (%)179.224178.923161.087176.469154.613
利息保障倍数 (X)140.801214.948194.19968.70939.733

营运能力分析
应收账款周转天数 (天)72.70871.86068.21364.93065.048
存货周转天数 (天)64.13062.92358.30957.58759.364